Target Ligand Binding Assays for TPD Development
* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.
Targeted protein degradation (TPD) has reshaped modern drug discovery by allowing researchers to eliminate disease-driving proteins instead of merely blocking them. Yet every degrader strategy—whether a PROTAC, molecular glue, LYTAC, AbTAC, ATTEC, or AUTAC—rises or falls on one step: the ligand has to engage its target with the right strength, residence time, and geometry. Target ligand binding assays sit at that foundation, providing the quantitative evidence behind warhead selection, linker optimization, E3 ligase recruitment, and ternary complex behavior. BOC Sciences delivers an integrated, biophysics-driven target ligand binding assay portfolio that helps medicinal chemists, structural biologists, and program leads move from initial hit confirmation to degrader candidate selection with data they can actually defend in a project review.
Request a Consultation Explore ServicesServices
BOC Sciences Target Ligand Binding Assay Services for TPD Development
Target Ligand Binding Affinity Measurement
We determine equilibrium dissociation constants (KD) between candidate warheads, E3 ligands, linkers, and full degraders and their protein targets using label-free surface and solution platforms. These data give project teams the first quantitative anchor for ranking ligands, choosing attachment chemistry, and deciding which series should advance into degrader synthesis.
Target Ligand Association and Dissociation Kinetics Analysis
Beyond equilibrium affinity, degrader success often hinges on how long a warhead stays on its target. We measure association (kon) and dissociation (koff) rates to reveal fast-on/fast-off versus slow-on/slow-off behavior, helping chemists balance residence time with cellular exposure and permeability.
Competitive Binding and Binding Site Confirmation
We design competitive displacement experiments using orthosteric probes, fluorescent tracers, or radiolabeled ligands to confirm warheads occupy the intended pocket and to explore allosteric or adjacent-site possibilities. This step is critical when moving from a screening hit to a chemistry series designed for linker attachment.
Target Ligand Binding Selectivity Profiling
Many TPD targets sit within protein families (kinases, bromodomains, nuclear receptors). We profile ligand binding across related paralogs and close homologs to flag potential off-target engagement early, supporting selectivity-driven design before degrader conjugation.
Target Ligand Binding Thermodynamics Analysis
Binding enthalpy (ΔH), entropy (ΔS), and stoichiometry (n) tell chemists whether affinity is driven by hydrogen bonding, hydrophobic collapse, or conformational restraint. We use calorimetric and van't Hoff analyses to expose the thermodynamic signature behind each ligand, which is especially useful when comparing warheads with similar KD values but very different physicochemical behavior.
Cellular Target Engagement Assessment
Even a perfect in vitro binder can fail in cells if it does not engage the target in its native context. We use cell-based thermal shift, proximity-based, and occupancy assays to confirm that warheads and degraders actually occupy the target inside the relevant cell line, bridging recombinant binding data with degradation outcomes.
Need Quantitative Target Ligand Binding Data for Your TPD Program?
From affinity ranking to cellular engagement, we help you connect every ligand decision to real binding evidence.
Modalities
Target Ligand Binding Assays for Different TPD Modalities
Target Ligand Binding Assays for PROTACs
Heterobifunctional PROTACs require simultaneous binding of a warhead to the protein of interest (POI) and a recruiter ligand to an E3 ligase. We measure both ends independently and in combination, so warhead chemistry can be optimized without losing sight of how it will cooperate with the E3 ligand and linker.
- POI binding affinity and kinetics for warhead selection
- E3 ligase binding confirmation for CRBN, VHL, IAP, MDM2 recruiters
- Binary-versus-ternary binding behavior across analog series
Target Ligand Binding Assays for Molecular Glue Degraders
Molecular glues induce or stabilize an interface between the target and an E3 ligase. Binding assays for these compounds must capture induced-fit behavior and very weak binary affinity that becomes productive only upon complex formation. Our platform combines binary binding reads with ternary complex analysis to reveal cooperative gain.
- Weak or undetectable binary binding capture using sensitive solution methods
- Induced-fit and cooperative binding quantification
- Substrate-versus-non-substrate discrimination at the E3 ligase interface
Target Ligand Binding Assays for LYTACs
LYTACs engage extracellular or membrane-associated proteins and route them through lysosomal pathways via a receptor-targeting moiety. We help teams confirm binding to both the disease target and the LYTAC receptor binder, supporting LYTAC degrader development with quantitative interaction data.
- Extracellular target and receptor-ligand binding confirmation
- Membrane-protein binding in cell-based and purified formats
- Receptor occupancy and competition analysis
Target Antigen Binding Assays for AbTACs
AbTACs are bispecific antibodies that connect a cell-surface target protein with a membrane-associated E3 ligase through their two binding arms. Binding assays here focus on antigen engagement, epitope accessibility, and bridging behavior, complementing AbTAC degrader design workflows where conformational and avidity effects dominate.
- Membrane antigen binding affinity and kinetics
- Bispecific bridging and ternary formation assays
- Cross-reactivity and species selectivity profiling
Target Protein and LC3 Binding Assays for ATTECs
ATTECs bring a substrate into proximity with LC3 to drive autophagosomal degradation. Binding assays must quantify both substrate recognition and the LC3 interaction, since productive degradation depends on a precise geometry between the two. Our work integrates with ATTEC development programs to map binding thermodynamics across bifunctional designs.
- Substrate-binding affinity and selectivity
- LC3 interaction confirmation and cooperativity analysis
- Bridging-driven complex stability evaluation
Target Recognition Binding Assays for AUTACs
AUTACs use a tag-based recognition strategy to flag substrates for selective autophagy. Binding assays focus on the recognition moiety and how it discriminates damaged or unwanted proteins from their healthy counterparts, supporting AUTAC degrader development with measured selectivity, not assumptions.
- Recognition-element binding affinity and selectivity
- Substrate-state-specific interaction profiling
- Off-target recognition risk assessment
Stages
Target Ligand Binding Assessment Across TPD Development Stages
Initial Target-Binding Ligand Screening
At the earliest stage, we screen focused or virtual hit libraries against the purified target to confirm which chemotypes actually bind. Workflows are designed for fast triage while preserving enough resolution to flag false positives caused by aggregation, fluorescence, or assay interference.
Target-Binding Ligand Optimization and Validation
Once confirmed hits exist, we apply kinetic, thermodynamic, and selectivity assays to guide structure–activity relationship (SAR) cycles. Each round of analog design is benchmarked against an agreed-upon reference ligand, so chemistry decisions are driven by binding data rather than intuition.
Linker-Modified Target Ligand Evaluation
Adding a linker exit point can change a warhead's binding mode. We compare parent ligand and linker-functionalized analog binding to identify which attachment sites preserve affinity and which disrupt it, supporting rational linker and exit-vector choice.
Final Degrader Target Binding Evaluation
For late-stage degraders, we re-confirm that the full bifunctional molecule still engages the target as designed and that any loss of binary affinity is compensated by ternary complex formation. This final binding check protects projects from advancing molecules whose activity is decoupled from target engagement.
Looking for a TPD Binding Assay Partner That Understands Each Stage?
Talk to our scientists about a staged plan—from hit triage to final degrader confirmation.
Why Essential
Why Target Ligand Binding Assays Are Essential for TPD Development?
Validate Binary Engagement Between Warhead and Target Protein
A degrader cannot work if its warhead never sits on the target. Binding assays convert a vague expectation of engagement into a measurable KD, kon, and koff, so program leads know whether their chemistry is on the right protein in the first place.
Confirm Productive Ternary Complex Formation With E3 Ligase
TPD is fundamentally a ternary event. Binary binding is necessary but rarely sufficient. Combining target binding with ternary complex assays reveals whether weak binders cooperate with the E3 ligase—or whether a strong binder actually blocks productive geometry.
Distinguish True Binders from Aggregation-Driven False Positives
Many PROTAC- and molecular glue-like scaffolds are large, lipophilic, and prone to colloidal aggregation. Our orthogonal biophysical readouts (SPR, ITC, MST, DSF) flag promiscuous behavior and protect medicinal chemistry teams from chasing artifacts instead of true affinity.
Support Quantitative SAR for PROTAC Warhead Optimization
Ranking analogs by cellular degradation alone is slow and noisy. Pairing degradation readouts with measured KD, residence time, and cooperativity turns SAR into a quantitative conversation, letting chemists see whether a structural change improved engagement, kinetics, or both.
Workflow
Target Ligand Binding Assay Workflow: From Sample to Binding Insight
01
Project Consultation and Assay Strategy Definition
We start by discussing target biology, TPD modality (PROTAC, molecular glue, LYTAC, AbTAC, ATTEC, AUTAC), existing ligand series, and the question the binding data needs to answer. Together we choose the platform mix that matches the sample type, throughput, and decision point.
02
Protein and Ligand Preparation and Quality Control
Whether proteins come from the client or are produced in our pipeline, we confirm identity, purity, folding, and activity before binding. Ligands are verified by mass and, where relevant, by solubility and stability checks so that assay failures can be interpreted rather than guessed.
03
Assay Development, Optimization, and Control Design
We optimize surface chemistry (for SPR/BLI), buffer composition, immobilization strategy, and probe labeling to maximize signal-to-noise. Reference ligands, negative controls, and inactive analogs are built into every study so binary binding can be distinguished from non-specific or aggregation-driven effects.
04
Binding Measurement Under Multi-Format Conditions
Single-concentration triage, full dose–response, single-cycle kinetics, and competition formats are run as needed. Temperature, cofactor, and salt conditions can be modulated to mimic cellular environments or to test robustness of binding.
05
Kinetic, Thermodynamic, and Cooperativity Data Analysis
Sensorgrams and titration curves are fit with appropriate models (1:1, heterogeneous ligand, two-state) to extract KD, kon, koff, ΔH, ΔS, stoichiometry, and cooperativity factor (α) where applicable. Every fit is reviewed by a senior scientist before reporting.
06
Integrated Reporting and Design Recommendation
Clients receive raw traces, fitted parameters, and a written interpretation that connects binding behavior to design choices—attachment site, linker length, exit vector, or replacement of the E3 ligand. Recommendations are framed for medicinal chemists, not just assay specialists.
07
Cellular Target Engagement Cross-Check
When project stage warrants it, recombinant binding data are confirmed in cells using thermal shift, proximity, or occupancy assays in the relevant line. This step protects against spending chemistry cycles on compounds that bind in a plate but never in a cell.
08
Follow-Up Support for Next-Generation Analogs
We retain reference ligands, assay conditions, and data so subsequent analog rounds can be benchmarked consistently. This continuity helps teams compare new chemistry against historical results without re-establishing baselines each cycle.
Ready to Build a Binding Assay Plan Around Your TPD Modality?
Share your target, ligand series, and stage—we will draft an assay plan within one working week.
Why Us
Why Choose BOC Sciences for Target Ligand Binding Assays?
Customized Assays for Different Target Proteins
We do not run a single template binding protocol across every project. Assay design—surface type, probe labeling, buffer, temperature, reference ligands—is tailored to each target class, whether that means a kinase, a bromodomain, a transcription factor, a multi-subunit complex, or a membrane protein.
Complementary Biophysical and Cell-Based Technologies
SPR, BLI, ITC, MST, DSF, FP, and cellular thermal shift assays can be combined when projects require orthogonal confirmation. Combining label-free surface readouts with solution-phase and cell-based methods protects clients from acting on a single artifact-prone technique.
Integrated Binding Analysis and Degrader Optimization Support
Binding data are interpreted in the context of degrader design: linker exit vectors, attachment chemistry, E3 ligand switching, cooperativity, and ternary complex behavior. Our scientists help clients translate numbers into the next set of analogs rather than handing over a chart without commentary.
Multi-Platform, Orthogonal Confirmation Strategy
When a project decision is high-stakes, we recommend at least two orthogonal readouts—for example, SPR plus ITC, or BLI plus MST—so binding conclusions do not rest on a single platform's quirks. This discipline is especially important for molecular glues and weak-binder regimes.
Transparent Data Delivery With Raw Traces and Fitted Parameters
Clients receive raw sensorgrams, titration isotherms, fitted parameters, and the methods behind each number. Reports are written for project review, not as a black-box certificate, so internal decisions about ligand progression can be defended.
Flexible Throughput From Single Compound to Library-Scale Screens
Whether a client needs a single KD value for one warhead or a 5,000-compound fragment-style triage across a target family, our workflows scale without forcing the project into the wrong format. Miniaturized formats are used where compound supply is limited.
Applications
Applications of Target Ligand Binding Assays in TPD Development
Target-Binding Warhead Screening and Selection
Confirm which chemotypes from a hit list truly engage the target, rank them by KD and residence time, and eliminate compounds whose apparent activity comes from aggregation or assay interference rather than real binding.
Linker Attachment Site and Warhead Optimization
Test parent ligand alongside linker-functionalized analogs to find attachment positions that preserve binding affinity and leave a clean exit vector for conjugation to an E3 ligand or recruiter.
Structure–Activity Relationship Studies
Quantify how each chemical modification changes affinity, kinetics, and thermodynamics across an analog matrix, supporting SAR-driven decisions in PROTAC, molecular glue, and other degrader series.
Target Binding Selectivity and Off-Target Investigation
Profile warhead binding across paralogs and related proteins to flag early selectivity risks, especially important in kinase, bromodomain, and nuclear receptor target families where selectivity is a competitive differentiator.
Cooperativity and Ternary Complex Stability Analysis
Compare binary binding of warhead and E3 ligand with ternary complex stability to extract cooperativity factor (α) and identify designs where productive complex formation outperforms the sum of binary interactions.
Hook-Effect and Bell-Shaped Curve Investigation
Use dose–response binding data to distinguish true bell-shaped behavior from solubility-driven artifacts, helping teams interpret cellular degradation curves and avoid misdiagnosing a hook effect where none exists.
Have a TPD Binding Question Your Current Data Cannot Answer?
Send us your target, ligand series, and the binding question—our scientists will suggest the shortest path to a defensible answer.
Case Study
Client Success Stories: Target Ligand Binding Assays
Project Background
A US-based oncology discovery team was advancing a CRBN-recruiting BRD4 PROTAC series for hematological cancer research. Despite strong cellular degradation data, analogs with similar BRD4 IC50 values showed very different cellular potency, and their BRD4 PROTAC lead series lacked a binary binding rationale for linker exit-vector choice.
Technical Challenges
PEG-based linkers complicated SPR immobilization and ITC heat budgets, and several analogs showed non-linear SPR sensorgrams suggestive of aggregation. The team also wanted to know whether weaker binders could still degrade BRD4 efficiently if their ternary complex cooperativity was higher.
BOC Sciences Solutions
- Multi-Platform Binary Binding Profiling: We ran 18 BRD4 PROTAC analogs on SPR, BLI, and ITC in matched buffer conditions, generating KD, kon, koff, ΔH, ΔS, and stoichiometry for each compound in a single comparative dataset.
- Aggregation and Artifact Counter-Screening: Each analog was counter-screened by DSF and a detergent-containing control to flag compounds whose apparent affinity collapsed in the presence of detergent, identifying three false-positive binders.
- Cooperativity and Ternary Complex Mapping: Binary binding data were integrated with ternary complex stability readouts to compute apparent cooperativity for each analog, separating compounds whose degradation came from binding alone versus those requiring cooperative gain.
Project Outcomes
The ranked dataset across 18 analogs showed that residence time (koff), not equilibrium affinity, drove cellular potency. Three false positives were deprioritized, and one analog with moderate KD but the longest residence time and highest cooperativity became the new lead, redirecting linker optimization toward exit vectors that preserved koff behavior.
Project Background
A Singaporean biotechnology company was exploring CRBN-binding molecular glue compounds that recruit CRBN to degrade IKZF1 (Ikaros) in lymphocyte models. Cellular degradation was reproducible, but binary binding to CRBN or IKZF1 was weak or undetectable, leaving their SAR without a binding anchor.
Technical Challenges
Molecular glues are hard to profile by binary binding alone because productive binding is often induced only at the E3 ligase interface. Conventional SPR and FP assays returned flat or noisy responses, while ITC consumed too much protein and compound.
BOC Sciences Solutions
- Sensitive Binary Binding Triage: We screened 14 CRBN-binding molecular glue analogs by MST and spectral shift at low label-to-protein ratios, capturing weak CRBN and IKZF1 binding that conventional SPR had missed, and identifying which chemotypes retained direct target engagement.
- Induced-Fit Cooperativity Quantification: Binary titrations were paired with CRBN-IKZF1 ternary complex titrations to derive an apparent cooperativity factor (α) for each analog, separating compounds with positive cooperativity from those acting through weak binary binding alone.
- Structure–Binding Relationship Interpretation: Binding thermodynamics, cooperativity, and cellular degradation data were combined into a single interpretive matrix, which we used together with the client to identify which molecular glue substituents drove induced interface formation versus those acting primarily through CRBN binding.
Project Outcomes
Of 14 analogs, five showed no detectable binary binding and were deprioritized, while three demonstrated clear induced cooperativity (α > 5). One of these combined the most favorable cooperativity with the lowest ITC compound consumption and advanced to the next profiling round, redirecting chemistry toward interface-stabilizing substituents.
Frequently Asked Questions (FAQ)
Does strong target binding always ensure efficient protein degradation?
No. Strong binary binding between a ligand and its target protein does not necessarily result in efficient degradation. For PROTACs, degradation also depends on E3 ligase recruitment, ternary complex geometry, cooperativity, ubiquitination efficiency, and intracellular compound availability. A degrader may show favorable binding affinity toward a purified target but limited degradation activity because of poor cellular access or unproductive ternary complex formation. Therefore, target ligand binding assays should be interpreted alongside binding kinetics, cellular target engagement, and protein degradation measurements. Combining these results helps researchers determine whether insufficient degradation arises from weak target recognition, ineffective recruitment, or downstream degradation mechanisms, providing a more reliable basis for degrader optimization.
Which assays best measure ligand affinity and binding kinetics?
Several complementary techniques can characterize interactions between target proteins and ligands, including surface plasmon resonance (SPR), bio-layer interferometry (BLI), microscale thermophoresis (MST), isothermal titration calorimetry (ITC), and fluorescence-based competition assays. SPR and BLI are particularly useful for measuring binding affinity and association and dissociation kinetics, providing parameters such as KD, kon, and koff when the interaction supports reliable fitting. MST enables interaction analysis in solution, while ITC provides additional thermodynamic information. The appropriate method depends on protein stability, ligand properties, binding strength, and assay requirements. For challenging targets or compounds susceptible to assay interference, combining independent measurement techniques can strengthen confidence in the binding results.
How do linker modifications influence target ligand binding?
Linker attachment can affect target ligand binding by changing steric accessibility, molecular flexibility, solvent exposure, and interactions near the binding pocket. A linker attached close to a critical recognition region may reduce binding affinity, while other modifications may influence association or dissociation kinetics without substantially changing equilibrium affinity. To understand these effects, researchers can compare the binding properties of the free target-binding ligand, linker-modified intermediates, and the final PROTAC. Evaluating different attachment positions, linker lengths, and chemical compositions helps identify modifications that preserve target recognition. These comparisons also help distinguish reduced target binding from limitations in subsequent ternary complex formation, supporting more informed warhead and linker optimization.
Can BOC Sciences customize assays for different TPD modalities?
Yes. BOC Sciences designs target ligand binding assays according to the molecular recognition mechanisms of different targeted protein degradation modalities. For PROTACs, we assess binary binding affinity and kinetics of free warheads and complete degraders. For molecular glue degraders, studies can examine ligand binding to the initiating protein and ligand-dependent target recruitment. For LYTACs and AbTACs, assay strategies focus on relevant cell-surface antigen and receptor interactions. ATTEC studies may investigate target protein and LC3 binding, while AUTAC evaluation emphasizes target recognition after molecular modification. Our scientists select appropriate biophysical, competition-based, and cell-based assays according to target properties, molecular architecture, and research objectives, helping clients obtain binding data relevant to their specific degradation mechanism.
How does BOC Sciences investigate weak cellular target engagement?
When a degrader shows favorable binding to a purified protein but weak cellular target engagement, BOC Sciences can design a stepwise investigation to identify possible causes. Our scientists first reassess direct target binding using SPR, BLI, or other suitable methods to examine affinity and potential assay interference. Cellular thermal shift assays, probe competition studies, or appropriate energy-transfer-based methods can then be used to investigate engagement in relevant cell models. Results are interpreted alongside compound accessibility, target localization, and changes in target abundance. For linker-modified degraders, we can also compare free ligand and final compound binding behavior. By integrating biochemical and cellular evidence, BOC Sciences helps clients identify likely limitations and develop practical strategies for further assay validation and degrader optimization.
Testimonials
Client Testimonials on Target Ligand Binding Assays
Reliable Binding Affinity Measurements
"We had been chasing one set of PROTAC analogs because of their cellular potency, but the binding data told a very different story. The orthogonal SPR and ITC comparison helped us retire three compounds and refocus on the chemistry that actually held the target."
— Dr. Bailey, Senior Scientist at a US-based Oncology Biotech
Valuable Insights into Linker Effects
"The team flagged that our preferred linker exit vector was already weakening BRD4 binding before we even conjugated the E3 ligand. That single observation saved us a full chemistry cycle and a lot of synthesis effort."
— Ms. Sullivan, Medicinal Chemistry Lead at a European Pharmaceutical Company
Effective Cellular Target Engagement Analysis
"Several of our warheads looked promising on recombinant protein but failed in cells. The cellular thermal shift and occupancy readouts gave us a clear ranking and explained why a few favorites were not progressing."
— Dr. Gonzales, Discovery Biology Director at an Asia-Pacific Research Institute
Customized Assays for Complex Targets
"We work on a multi-subunit transcription factor complex that most CROs are not set up to handle. They built a tailored assay around our construct, ran it carefully, and delivered interpretable numbers instead of a black-box report."
— Dr. Brennan, Project Lead at a UK-based Translational Research Organization
* PROTAC® is a registered trademark of Arvinas Operations, Inc., and is used under license.
BOC Sciences Support
Please contact us with any specific requirements and we will get back to you as soon as possible.
